Aminopyridine Treatment in a Patient With Bilateral Vestibular Failure and Cryptogenic Downbeat Nystagmus

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F12%3A43896082" target="_blank" >RIV/00216208:11120/12:43896082 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064173:_____/12:43896082

Výsledek na webu

<a href="http://dx.doi.org/10.1097/WNO.0b013e31824f397f" target="_blank" >http://dx.doi.org/10.1097/WNO.0b013e31824f397f</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/WNO.0b013e31824f397f" target="_blank" >10.1097/WNO.0b013e31824f397f</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Aminopyridine Treatment in a Patient With Bilateral Vestibular Failure and Cryptogenic Downbeat Nystagmus

Popis výsledku v původním jazyce

In a recent issue of this journal, Kalla et al (1) reported that 4-aminopyridine (4-AP) alleviates the symptoms of downbeat nystagmus (DBN) significantly more than 3,4-diaminopyridine (3,4-DAP). Both drugs are potassium-channel blockers, but 4-aminopyridine is lipid-soluble and more easily crosses the blood-brain-barrier. 3,4-diaminopyridine is not lipid soluble, with direct effects in the peripheral nervous system and indirect effects in the central nervous system via its metabolites (1,2). In the report by Kalla et al (1), 1 male patient suffered from bilateral vestibular failure (disorder of the peripheral nervous system) as well as DBN (disorder of the central nervous system). We now document this case in detail. At the time of the study, the patient was 58 years old. Ten years earlier, he had traveled to Indonesia, where he suffered from extreme diarrhea with severe weight loss, followed by the development of tinnitus, oscillopsia, postural instability, and bilateral vestibular fa

Název v anglickém jazyce

Aminopyridine Treatment in a Patient With Bilateral Vestibular Failure and Cryptogenic Downbeat Nystagmus

Popis výsledku anglicky

In a recent issue of this journal, Kalla et al (1) reported that 4-aminopyridine (4-AP) alleviates the symptoms of downbeat nystagmus (DBN) significantly more than 3,4-diaminopyridine (3,4-DAP). Both drugs are potassium-channel blockers, but 4-aminopyridine is lipid-soluble and more easily crosses the blood-brain-barrier. 3,4-diaminopyridine is not lipid soluble, with direct effects in the peripheral nervous system and indirect effects in the central nervous system via its metabolites (1,2). In the report by Kalla et al (1), 1 male patient suffered from bilateral vestibular failure (disorder of the peripheral nervous system) as well as DBN (disorder of the central nervous system). We now document this case in detail. At the time of the study, the patient was 58 years old. Ten years earlier, he had traveled to Indonesia, where he suffered from extreme diarrhea with severe weight loss, followed by the development of tinnitus, oscillopsia, postural instability, and bilateral vestibular fa

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FF - ORL, oftalmologie, stomatologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Neuro-Ophthalmology

ISSN

1070-8022

e-ISSN

—

Svazek periodika

32

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

1

Strana od-do

190

Kód UT WoS článku

000304790500019

EID výsledku v databázi Scopus

—